Overview |
bs-2208R |
IL-33 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human IL-33 |
1-111/270 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
90865 |
O95760 |
Cytoplasm, Nucleus, Secreted |
Interleukin-33/Nuclear factor from high endothelial venules; IL33; C9orf26; CHROMOSOME 9 OPEN READING FRAME 26; DKFZp586H0523; DVS27; DVS27 related protein; IL 1F11; IL 33; IL1F11; Interleukin 1 family member 11; Interleukin 33; INTERLEUKIN 33 NFHEV; Interleukin 33 precursor; Interleukin33; NF HEV; NFEHEV; NFHEV; Nuclear factor from high endothelial venules; RP11 575C20.2 IL33_HUMAN. |
IL33 is a cytokine which belongs to the IL-1 superfamily, and it induces helper T cells to produce type 2 cytokines. This cytokine was previously named NF-HEV 'nuclear factor (NF) in high endothelial venules' (HEVs), as it was originally identified in these specialized cells.IL33 mediates its biological effects by interacting with the receptors ST2 and IL-1 Receptor Accessory Protein, activating intracellular molecules in the NF-kappaB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-4, IL-5 and IL-13) from polarized Th2 cells. The induction of type 2 cytokines by IL-33 in vivo is believed to induce the the severe pathological changes observed in mucosal organs following administration of IL33. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |